Total Payments
$828,295
2024 Payments
$70,776
Companies
33
Transactions
1,376
Medicare Patients
793
Medicare Billing
$87,065
Payment Breakdown by Category
Other$446,927 (54.0%)
Consulting$295,406 (35.7%)
Travel$55,120 (6.7%)
Food & Beverage$30,475 (3.7%)
Education$367.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $404,586 | 189 | 48.8% |
| Consulting Fee | $295,406 | 112 | 35.7% |
| Travel and Lodging | $55,120 | 221 | 6.7% |
| Honoraria | $42,300 | 12 | 5.1% |
| Food and Beverage | $30,475 | 838 | 3.7% |
| Education | $367.00 | 3 | 0.0% |
| Grant | $41.50 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $231,662 | 331 | $0 (2024) |
| Allergan, Inc. | $150,536 | 187 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $136,228 | 169 | $0 (2024) |
| ABBVIE INC. | $118,973 | 216 | $0 (2024) |
| Amgen Inc. | $93,938 | 124 | $0 (2024) |
| Lundbeck LLC | $26,203 | 32 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $21,254 | 150 | $0 (2020) |
| H. Lundbeck A S | $10,625 | 2 | $0 (2023) |
| BioDelivery Sciences International, Inc. | $9,347 | 15 | $0 (2021) |
| PFIZER INC. | $7,599 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,776 | 142 | ABBVIE INC. ($31,093) |
| 2023 | $103,784 | 184 | Lilly USA, LLC ($54,586) |
| 2022 | $33,680 | 94 | AbbVie Inc. ($24,282) |
| 2021 | $127,645 | 103 | Allergan, Inc. ($40,082) |
| 2020 | $206,042 | 226 | Allergan, Inc. ($92,765) |
| 2019 | $174,020 | 357 | Lilly USA, LLC ($78,614) |
| 2018 | $93,448 | 184 | Amgen Inc. ($36,062) |
| 2017 | $18,901 | 86 | Amgen Inc. ($13,592) |
All Payment Transactions
1,376 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 12/27/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $30.71 | General |
| 12/20/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 12/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: PAIN | ||||||
| 12/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: PAIN | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: Central Nervous System | ||||||
| 12/09/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 11/27/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.54 | General |
| Category: NEUROLOGY | ||||||
| 11/23/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $135.36 | General |
| Category: PAIN | ||||||
| 11/20/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $9.84 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $0.46 | General |
| Category: NEUROSCIENCE | ||||||
| 11/16/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $39.72 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $116.00 | General |
| Category: NEUROLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: Central Nervous System | ||||||
| 11/05/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | Cash or cash equivalent | $119.33 | General |
| Category: PAIN | ||||||
| 11/02/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $472.85 | General |
| Category: PAIN | ||||||
| 11/02/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $401.40 | General |
| Category: PAIN | ||||||
| 11/02/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $381.26 | General |
| Category: PAIN | ||||||
| 11/02/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $339.00 | General |
| Category: PAIN | ||||||
| 10/23/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $17.39 | General |
| Category: NEUROLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $3.22 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 168 | 222 | $70,600 | $19,470 |
| 2022 | 7 | 198 | 249 | $71,350 | $22,204 |
| 2021 | 6 | 172 | 244 | $63,460 | $21,583 |
| 2020 | 9 | 255 | 329 | $94,400 | $23,808 |
Total Patients
793
Total Services
1,044
Medicare Billing
$87,065
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Facility | 2023 | 27 | 55 | $23,925 | $5,534 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 55 | $15,125 | $3,855 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 42 | 42 | $11,550 | $2,875 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 29 | $5,510 | $2,556 | 46.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $5,040 | $1,991 | 39.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 15 | $5,250 | $1,458 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 12 | $4,200 | $1,200 | 28.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Facility | 2022 | 35 | 61 | $26,535 | $6,175 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 60 | 68 | $14,200 | $4,612 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 25 | $7,420 | $2,800 | 37.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 39 | $5,070 | $2,242 | 44.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $4,680 | $2,106 | 45.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $4,680 | $1,850 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 19 | $5,045 | $1,366 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $3,720 | $1,055 | 28.4% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Facility | 2021 | 27 | 67 | $29,145 | $7,230 | 24.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 50 | 62 | $11,470 | $4,749 | 41.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 22 | 25 | $6,375 | $2,958 | 46.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $7,665 | $2,876 | 37.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 36 | $4,680 | $2,204 | 47.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 29 | 33 | $4,125 | $1,566 | 38.0% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Facility | 2020 | 52 | 81 | $35,235 | $8,713 | 24.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 57 | 73 | $13,505 | $4,731 | 35.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 23 | $5,865 | $2,132 | 36.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $3,960 | $1,934 | 48.8% |
About Dr. Stephanie Nahas-Geiger, M.D
Dr. Stephanie Nahas-Geiger, M.D is a Neurology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1033265004.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephanie Nahas-Geiger, M.D has received a total of $828,295 in payments from pharmaceutical and medical device companies, with $70,776 received in 2024. These payments were reported across 1,376 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($404,586).
As a Medicare-enrolled provider, Nahas-Geiger has provided services to 793 Medicare beneficiaries, totaling 1,044 services with total Medicare billing of $87,065. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Philadelphia, PA
- Active Since 01/25/2007
- Last Updated 05/22/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1033265004
Products in Payments
- UBRELVY (Drug) $110,028
- BOTOX (Biological) $97,429
- AJOVY (Biological) $83,991
- Aimovig (Biological) $69,991
- AJOVY (Drug) $47,726
- EMGALITY (Drug) $37,431
- VYEPTI (Biological) $29,572
- REYVOW (Drug) $25,470
- TROKENDI XR (Drug) $21,150
- QULIPTA (Drug) $10,724
- NURTEC ODT (Drug) $10,279
- ELYXYB - CELECOXIB (Drug) $9,347
- ZEMBRACE SYMTOUCH (Drug) $3,830
- AIMOVIG (Biological) $2,971
- BOTOX (Drug) $1,403
- Trudhesa (Drug) $441.67
- BOTOX CHRONIC MIGRAINE (Drug) $324.19
- Zembrace (Drug) $283.13
- Austedo XR (Drug) $186.07
- COMIRNATY (Biological) $180.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Philadelphia
Dr. Thomas Leist, M.d, M.D
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Daniel Kremens, M.d., J.d, M.D., J.D
Neurology — Payments: $1.9M
Neurology $1.9M
Dr. Jill Giordano Farmer, Do, DO
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Stephen Silberstein, M.d, M.D
Neurology — Payments: $936,801
Neurology $936,801
Amit Bar-Or
Neurology — Payments: $904,147
Neurology $904,147
Matthew Stern, Md, MD
Neurology — Payments: $517,599
Neurology $517,599